Home Articles List Article Information
ALEXMED ePosters
Journal Archive
Volume Volume 6 (2024)
Volume Volume 5 (2023)
Volume Volume 4 (2022)
Volume Volume 3 (2021)
Volume Volume 2 (2020)
Volume Volume 1 (2019)
Shaala, I., Deghady, A., Meheissen, M., Hussien, E. (2023). EVALUATION OF HEPARANASE PROCOAGULANT ACTIVITY AND TISSUE FACTOR PATHWAY INHIBITOR LEVEL IN UTERINE CANCER PATIENTS. ALEXMED ePosters, 5(1), 16-17. doi: 10.21608/alexpo.2023.191344.1553
Iglal Shaala; Akram Abdelmoneim Deghady; Mohamed Ahmed Meheissen; Esraa Mohammed Hussien. "EVALUATION OF HEPARANASE PROCOAGULANT ACTIVITY AND TISSUE FACTOR PATHWAY INHIBITOR LEVEL IN UTERINE CANCER PATIENTS". ALEXMED ePosters, 5, 1, 2023, 16-17. doi: 10.21608/alexpo.2023.191344.1553
Shaala, I., Deghady, A., Meheissen, M., Hussien, E. (2023). 'EVALUATION OF HEPARANASE PROCOAGULANT ACTIVITY AND TISSUE FACTOR PATHWAY INHIBITOR LEVEL IN UTERINE CANCER PATIENTS', ALEXMED ePosters, 5(1), pp. 16-17. doi: 10.21608/alexpo.2023.191344.1553
Shaala, I., Deghady, A., Meheissen, M., Hussien, E. EVALUATION OF HEPARANASE PROCOAGULANT ACTIVITY AND TISSUE FACTOR PATHWAY INHIBITOR LEVEL IN UTERINE CANCER PATIENTS. ALEXMED ePosters, 2023; 5(1): 16-17. doi: 10.21608/alexpo.2023.191344.1553

EVALUATION OF HEPARANASE PROCOAGULANT ACTIVITY AND TISSUE FACTOR PATHWAY INHIBITOR LEVEL IN UTERINE CANCER PATIENTS

Article 1, Volume 5, Issue 1, January 2023, Page 16-17  XML
Document Type: Preliminary preprint short reports of original research
DOI: 10.21608/alexpo.2023.191344.1553
View on SCiNiTO View on SCiNiTO
Authors
Iglal Shaala1; Akram Abdelmoneim Deghady2; Mohamed Ahmed Meheissen3; Esraa Mohammed Hussien email 2
1Department of Clincal and chemical
2Clinical and chemical pathology department, faculty of medicine, university of Alexandria
3Oncology and nuclear medicine deartment faculty of medicine, university of Alexandria
Abstract
Endometrial cancer is considered one of the most common malignancies in females worldwide. The majority of endometrial cancers are estrogen related. Early detection of uterine cancer will provide the patient with better chance of survival while discovering the disease at late stage or after metastatic spread will significantly increase the morbidity and the risk of complications.Hemostasis is a complex physiological process and to achieve normal hemostasis, delicate balance between clotting cascade and fibrinolytic cascade is required to prevent thrombosis or hemorrhage. Heparanase is an endoglycosidase enzyme which cleaves heparane sulphate, it is expressed in human tumors. Heparanase upregulation correlates with increased tumor vascularity and poor postoperative survival of cancer patients so heparanase is implicated in angiogenesis and tumor progression.It is now well established that the prime trigger to blood coagulation is tissue factor (TF) that is exposed on the surface of fibroblasts as a result of vessel wall injury. TFPI binds to factor Xa and, in this combination, binds to and inhibits tissue factor/factor VIIa complex and activated FX (FXa) and thus TFPI is currently being included as a natural coagulation inhibitor..
Keywords
Heparanase; TFPI; Thromboembolic events
Supplementary Files
Statistics
Article View: 84